Vertex Pharmaceuticals Incorporated (VRTX)
| Market Cap | 91.26B |
| Revenue (ttm) | 9.65B |
| Net Income (ttm) | 3.47B |
| Shares Out | 257.68M |
| EPS (ttm) | 13.32 |
| PE Ratio | 26.54 |
| Forward PE | 20.58 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 913,899 |
| Open | 355.28 |
| Previous Close | 354.15 |
| Day's Range | 351.11 - 356.33 |
| 52-Week Range | 282.21 - 387.42 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 372.96 (+5.52%) |
| Earnings Date | Nov 6, 2023 |
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company'... [Read more]
Financial Performance
In 2022, VRTX's revenue was $8.93 billion, an increase of 17.91% compared to the previous year's $7.57 billion. Earnings were $3.32 billion, an increase of 41.84%.
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for VRTX stock is "Buy." The 12-month stock price forecast is $372.96, which is an increase of 5.52% from the latest price.
News
Vertex Appoints Nancy Thornberry to its Board of Directors
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberr...
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration
Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency (EMA) has validated a Type II variation application to the Marketing Authorization for...
European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/...
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking p...
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healt...
Why you can make Vertex Pharmaceuticals a buy on any pullback
Shares of Vertex Pharmaceuticals, Inc. NASDAQ: VRTX are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a slight miss...
Vertex Pharma misses sales estimates on weak demand for older CF treatments
Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.
Vertex Reports Third Quarter 2023 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2023, raised full year 2023 guidance...
England's young cystic fibrosis patients face new treatment worry
Young English sufferers of cystic fibrosis (CF) face new uncertainty after regulators published proposals which, if enacted, would restrict access to potentially life-changing treatments on cost groun...
Vertex to Present New Data on Exagamglogene Autotemcel (exa-cel) at the American Society of Hematology (ASH) Annual Meeting and Exposition
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that seven abstracts have been accepted for presentation at the 2023 American Society of Hematology (ASH) An...
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying caus...
FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after appr...
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patients
The decision by an advisory committee may lead to Food and Drug Administration approval of the first treatment for humans that uses the CRISPR gene-editing system.
FDA Advisors Consider Crispr Gene-Editing Treatment for Sickle Cell Anemia
Nearly all patients treated so far have been relieved of the blood-clogging crises of the disease.
Vertex to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charles Wagner, Executive Vice President and ...
Vertex to Announce Third Quarter 2023 Financial Results on November 6
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2023 financial results on Monday, November 6, 2023 after the financial markets close. The comp...
Cramer's Mad Dash: Vertex Pharmaceuticals
CNBC's Jim Cramer delivers his daily Mad Dash.
Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
CNBC's Jim Cramer said investors keep an eye on Vertex Pharmaceuticals (VRTX) as the company develops a non-opioid pain drug.
Vertex Appoints Michel Lagarde to its Board of Directors
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is ...
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigat...
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a p...
Vertex Researchers Awarded 2024 Breakthrough Prize in Life Sciences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that three of its researchers have been awarded the 2024 Breakthrough Prize in Life Sciences “for developing...
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today annou...